We assessed cancer incidence during 5 years of follow-up in patients with atrial fibrillation in Denmark using a factor Xa inhibitor (n = 11,742) or a thrombin inhibitor (dabigatran) (n = 11,970) for stroke prevention. This evidence concerns the gene F10 and cancer.